| Trial ID: | L7180 |
| Source ID: | NCT01212133
|
| Associated Drug: |
Liraglutide
|
| Title: |
A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India
|
| Acronym: |
Lead-In
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: liraglutide
|
| Outcome Measures: |
Primary: The number of serious adverse drug reactions (SADRs) during the study period, during 26 weeks of treatment | Secondary: The number of adverse drug reactions (ADR) during the study period, during 26 weeks of treatment|The number of serious adverse events (SAE) during the study period, during 26 weeks of treatment|Frequency of hypoglycaemic episodes, during 26 weeks of treatment
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
1386
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2010-11
|
| Completion Date: |
2012-04
|
| Results First Posted: |
|
| Last Update Posted: |
2016-12-16
|
| Locations: |
Novo Nordisk Investigational Site, Bangalore, 560001, India
|
| URL: |
https://clinicaltrials.gov/show/NCT01212133
|
